The Korean Society for the Study of Obesity (KSSO) is now busy revising its guidelines ahead of Novo Nordisk's anticipated domestic launch of its obesity treatment Wegovy (semaglutide) late this year.According to a recent seminar of the Guidelines Committee at the KSSO’s 59th spring conference, the
Korean pharmaceutical companies are announcing their general shareholders’ meeting schedules.According to the Kosdaq Listed Companies Association, the key dates for shareholder meetings in 2024 are March 22, 27, and 29, when the domestic drugmakers hold annual shareholder meetings.In these meetings,
Liveome, an affiliate of Medytox, said it completed the phase 1 clinical trial in Australia for its gene-recombinant microbiome drug, LIV001.The drug is being developed as a treatment for inflammatory bowel disease, a chronic immune disorder that has been challenging to manage with existing therapie
HK inno.N is embroiled in a crisis rumor after it lost the first round of patent litigation for the crystalline form of its P-CAB-based gastroesophageal reflux disease (GERD) drug, K-CAB Tab (tegoprazan).However, the company denied such concerns, expressing confidence about the continued growth of K
Dx&Vx, a diagnostics and vaccine company, said Tuesday that its Chinese subsidiary, Dx&Vx BJ, has set 2024 revenue and operating profit ratio targets of 38 billion won ($29 million) and 25 percent, respectively.In its first full year of operation last year, Dx&Vx BJ achieved sales of 14.8 billion wo
Professors from Seoul National University (SNU) College of Medicine have proposed forming a consultative body to resolve the ongoing medical turmoil, which would include the government, the medical community, lawmakers, medical residents, and civic groups representing the public.They also suggested
"Korea is known for its successful clinical trials. However, underneath it is Korea’s characteristics of frequently delayed reimbursement for new drugs. I think part of it is to ensure access to new drugs by participating in clinical trials."Ingrid A. Mayer, vice president of global clinical strateg
The government's push to increase the medical school enrollment quota has led to the departure of most medical residents from training hospitals, forcing various medical societies to cancel annual workshops for new interns and residents.Kim Seung-hyun, president of the Korean Neurological Associatio
The government's deployment of public health doctors and military surgeons to fill healthcare gaps in teaching hospitals has sparked confusion and dissatisfaction from day one.Deployed public health and military doctors are upset because they are being treated poorly, including housing, and are forc
The challenge with preparing “twigim” -- the Korean street food similar to Japanese tempura -- at home lies in managing the leftover oil. Disposing of it after a single use can feel wasteful. Therefore, the question arises: how many times can oil for frying be reused? The answer is contingent upon s
A team of researchers from Yonsei University, Severance Hospital, and Gangnam Severance Hospital has developed a high-safety, liquid metal-based soft artificial retina.This innovative technology promises to restore vision to patients blinded by retinal diseases, including retinitis pigmentosa and ma
Korean pharmaceutical and biotechnology companies are set to present their latest studies at the American Association for Cancer Research (AACR) Annual Meeting 2024.The AACR meeting, established in 1907 and regarded as one of the world's top three cancer conferences alongside those of the American S
The National Cancer Center (NCC) said it has discovered a biomarker that can distinguish pancreatic cancer patients from healthy individuals "with 100 percent accuracy" and has licensed out the biomarker to New Cancer Cure Bio.The biomarkers X-100 and X-99 have shown the capability to accurately dif
Hanmi Pharmaceutical said it has submitted an investigational new drug (IND) application for a phase 1 clinical trial of its obesity treatment candidate HM15275 to the Ministry of Food and Drug Safety (MFDS). Hanmi also plans to submit the IND application to the U.S. FDA this month.HM15275 is an obe
The decision on Korean medical school professors' application for an injunction to suspend execution and stop the government’s increase in the medical school enrollment quota will likely come as early as Friday. All parties involved in the ongoing medical turmoil are keenly watching to see if the co
ST Pharm and LegoChem Biosciences have entered into a contract for joint research and manufacturing of antibody drug conjugate (ADC) linkers.Under the accord, ST Pharm plans to provide contract development and manufacturing organization (CDMO) services covering the entire production process based on
Celltrion said it has completed its application to the U.S. FDA for the approval of CT-P39, a biosimilar referencing Xolair (ingredient: omalizumab). Xolair was developed by Genentech and Novartis for the treatment of allergic asthma, chronic rhinosinusitis with nasal polyposis, and chronic idiopath
MSD's anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been approved for the first-line treatment of HER2-negative gastric cancer following BMS’s Opdivo (nivolumab).MSD Korea said Monday that Keytruda received approval from the Ministry of Food and Drug Safety (MFDS) last Wednesday for an expand
GSK's Jemperli (dostarlimab) has secured the first-line treatment indication for endometrial cancer ahead of MSD's Keytruda (pembrolizumab), becoming the first immunotherapy in Korea to be approved for both first- and second-line treatment.GSK Korea said its endometrial cancer drug Jemperli had rece
Lunit, a medical artificial intelligence (AI) company, said Monday that it has signed contracts to provide AI image analysis solutions for cancer diagnosis to Chung Shan Medical University in Taiwan and a large hospital in Singapore.The company said that with these contracts, Lunit plans to strength